Survival outcomes of combined hepatocellular‐cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: A SEER population‐based cohort study

Yang, Zhen; Shi, Guangjun

doi:10.1002/cam4.4474

Cited by 8 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, although the survival of the ICC patients increased over time, their median survival was still only 14 months. Currently, there is a lack of effective treatment for ICC to prolong patient outcomes ( 16 , 17 ).…”

Section: Discussionmentioning

confidence: 99%

Incidence trend and prognosis of intrahepatic cholangiocarcinoma: a study based on the SEER database

Yang,

Wang,

2023

Transl Cancer Res

View full text Add to dashboard Cite

Background Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer after hepatocellular carcinoma (HCC). ICC and HCC have different cellular origins; therefore, ICC is significantly different from HCC in terms of aetiology, mechanism, tumour biological behaviour, treatment methods, and prognosis. The objective of this study was to investigate the current incidence trend and prognosis of ICC and deepen the understanding of ICC. Methods A large sample of ICC and HCC patient data was obtained from the Surveillance, Epidemiology and End Results (SEER) database of the National Cancer Institute (NCI), USA. The incidence trend, prognosis, and the effect of surgery and lymph node dissection on the prognosis of ICC patients were analysed. Results In recent years, the incidence of ICC has increased. The treatment effect of ICC patients has been significantly improved. But the prognosis of ICC patients is significantly worse than that of HCC patients. Surgery can benefit all stages of ICC, and lymph node dissection is beneficial for the prognosis of patients with positive lymph nodes (N1). Conclusions In recent years, the incidence of ICC has been increasing, and its prognosis remains poor, which is a cause for concern. We need to understand the epidemiological and pathophysiological characteristics of ICC and explore more effective treatment methods to improve the efficacy of treatment for ICC patients and prolong their survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence trend and prognosis of intrahepatic cholangiocarcinoma: a study based on the SEER database

Yang,

Wang,

2023

Transl Cancer Res

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence trend and prognosis of intrahepatic cholangiocarcinoma: a study based on the SEER database

Yang

Wang

Zhou

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) have different cellular origins; therefore, ICC is significantly different from HCC in terms of aetiology, mechanism, tumour biological behaviour, treatment methods, and prognosis. The objective of this study was to investigate the current incidence trend and prognosis of intrahepatic cholangiocarcinoma (ICC) and deepen the understanding of ICC. Methods A large sample of ICC and hepatocellular carcinoma (HCC) patient data was obtained from the Surveillance, Epidemiology and End Results (SEER) database of the National Cancer Institute (NCI), USA. The incidence trend, prognosis, and the effect of surgery and lymph node dissection on the prognosis of ICC patients were analysed. Results In recent years, the incidence of ICC has increased. The prognosis of ICC patients is significantly worse than that of HCC patients. Surgery can benefit all stages of ICC, and lymph node dissection is beneficial for the prognosis of patients with positive lymph nodes (N1). Conclusion In recent years, the incidence of ICC has been increasing, and its prognosis remains poor, which is a cause for concern.

show abstract

“…The treatment of cHCC-CCA has not been standardized in comparison to HCC and ICC, and a number of therapy strategies have been suggested. Radical tumor resection and lymph node dissection are the only curative options for patients with cHCC-CCA[ 7 , 8 ]. Nonetheless, the 5-year survival rate does not reach 30%, and the tumor recurrence rate is considerable (up to 80% after 5 years) in most studies[ 9 - 11 ].…”

Section: Introductionmentioning

confidence: 99%

Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study

Zhang¹,

Chen²,

Yang³

et al. 2022

World J Gastroenterol

View full text Add to dashboard Cite

BACKGROUND Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a form of rare primary liver cancer that combines intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma. AIM To investigate overall survival (OS) and recurrence-free survival (RFS) after radical resection in patients with cHCC-CCA, and the clinicopathological factors affecting prognosis in two center hospitals of China. METHODS We reviewed consecutive patients with cHCC-CCA who received radical resection between January 2005 and September 2021 at Peking Union Medical College and the 5th Medical Center of the PLA General Hospital retrospectively. Regular follow-up and clinicopathological characteristics were systematic collected for baseline and prognostic analysis. RESULTS Our study included 95 patients who received radical resection. The majority of these patients were male and 82.7% of these patients were infected with HBV. The mean tumor size was 4.5 cm, and approximately 40% of patients had more than one lesion. The median OS was 26.8 (95%CI: 18.5-43.0) mo, and the median RFS was 7.27 (95%CI: 5.83-10.3) mo. Independent predictors of OS were CA19-9 ≥ 37 U/mL (HR = 8.68, P = 0.002), Child-Pugh score > 5 (HR = 5.52, P = 0.027), tumor number > 1 (HR = 30.85, P = 0.002), tumor size and transarterial chemoembolization (TACE) after surgery (HR = 0.2, P = 0.005). CONCLUSION The overall postoperative survival of cHCC-CCA patients is poor, and most patients experience relapse within a short period of time after surgery. Preoperative tumor biomarker (CA19-9, alpha-fetoprotein) levels, tumor size, and Child-Pugh score can significantly affect OS. Adjuvant TACE after surgery prolongs RFS, suggesting that TACE is a possible option for postoperative adjuvant therapy in patients with cHCC-CCA.

show abstract

Survival outcomes of combined hepatocellular‐cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: A SEER population‐based cohort study

Cited by 8 publications

References 36 publications

Incidence trend and prognosis of intrahepatic cholangiocarcinoma: a study based on the SEER database

Incidence trend and prognosis of intrahepatic cholangiocarcinoma: a study based on the SEER database

Incidence trend and prognosis of intrahepatic cholangiocarcinoma: a study based on the SEER database

Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study

Contact Info

Product

Resources

About